



ViroGates announces a capital increase in connection with the exercise of warrants

26.6.2020 12:13:09 CEST | ViroGates | Company Announcement

Company announcement no. 16-2020 - 26 June 2020

Birkerød, Denmark - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces a capital increase by a nominal amount of DKK 81,156, divided into 81,156 new shares with a nominal value of DKK 1 each, in connection with the exercise of warrants.

In 2018, ViroGates issued 216,959 warrants in a warrant program associated with a convertible loan. Shareholders who converted their loan into shares under the convertible loan, were granted warrants according to the shares acquired. The warrants of this program vested immediately. Each warrant entitled the holder to subscribe for one share in the Company with a nominal value of DKK 1.

The said warrants could be exercised until yesterday 25th of June 2020 and, consequently, unexercised warrants have lapsed.

ViroGates has received notice of exercise of warrants as follows:

Warrant holder	Number of exercised warrants	Exercise price per warrant (DKK)	Exercise price paid (DKK)	No of Shares
N.P. Louis-Hansen ApS	81,156	91	7,385,196	81,156

Today ViroGates' Board of Directors decided to carry out the capital increase relating to the exercised warrants.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares hold rights to dividends and other rights from the time of the warrant holder's exercise notice. ViroGates only has one class of shares.

The new shares are expected to be admitted to trading and official listing on NASDAQ First North Growth Market Copenhagen A/S after registration with the Danish Business Authority during the week commencing 29 June 2020 under the ISIN code for ViroGates A/S' shares (DK0061030574).

Pursuant to section 32 of the Danish Capital Markets Act, it is hereby announced that the total nominal value of ViroGates A/S' share capital increases from DKK 3,044,270 to 3,125,426 after the capital increase. The share capital is thus made up of 3,125,426 shares of a nominal value of DKK 1 each, and one vote each, corresponding to a total of 3,125,426 votes.

The remaining 135,803 warrants under this warrant program lapsed unexercised yesterday the 25th of June 2020.

The announcement can be found at <https://www.virogates.com/investor/announcements>

For further information please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

- Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com

Attachments

- [20200626-ViroGates Company announcement 16.pdf](#)